Download Library

 
 
 
Download Library
Document Type
Interim Safety Analysis of a Phase II Randomized Study of Daratumumab, Lenalidomide, Bortezomib and Dexamethasone vs Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for HDT and ASCT- ASH poster - December 2017 (Voorhees)
PDF
147.9 KB
Results of an Interim Safety Analysis of a Phase II Study of Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone in Previously Untreated and Relapsed Patients with Multiple Myeloma - ASH poster - December 2017 (Yimer)
PDF
198.8 KB
Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma in Patients with greater than or equal to 2 Prior Lines of Therapy: Updated Analysis of MMY1001 - ASH poster - December 2017 (Facon)
PDF
475.6 KB
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX - ASH poster - December 2017 (Moreau)
PDF
632.5 KB
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma Patients: An Update of Overall Survival in CASTOR - ASH poster - December 2017 (Lentzsch)
PDF
449.5 KB
Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results - ASH poster - December 2017 (Plesner)
PDF
374.4 KB
Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (MM1001) - ASH poster - December 2017 (Lonial)
PDF
407.3 KB
Citi 2017 Global Healthcare Conference - December 2017
PDF
2.6 MB
Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone vs Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant (ALCYONE) - ASH abstract - November 2017 (Mateos)
URL
N/A
Jefferies London Healthcare Conference, London, UK
PDF
2.4 MB
Q3 2017 Results Podcast
MP3
29.1 MB
Genmab First Nine Months of 2017 Results Presentation
PDF
792.8 KB
Interim Report for the First Nine Months of 2017
pdf
589.5 KB
A Phase IIa Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy - ESGO E-poster - November 2017 (Concin)
PDF
453.8 KB
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy & Safety Analysis of POLLUX - ASH abstract - November 2017 (Dimopoulos)
URL
N/A
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma Patients: An Update of Overall Survival in CASTOR - ASH abstract - November 2017 (Lentzsch)
URL
N/A
Interim Safety Analysis of a Phase II Randomized Study of Daratumumab, Lenalidomide, Bortezomib and Dexamethasone vs Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for HDT and ASCT- ASH abstract -November 2017 (Voorhees)
URL
N/A
Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and SIRIUS - ASH abstract - November 2017 (Usmani)
URL
N/A
Daratumumab Monotherapy for Patients with Intermediate or High-risk Smoldering Multiple Myeloma: CENTAURUS - ASH abstract - November 2017 (Hofmeister)
URL
N/A
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX - ASH abstract - November 2017 (Moreau)
URL
N/A
Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Lonial)
URL
N/A
Results of an Interim Safety Analysis of a Phase II Study of Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone in Previously Untreated and Relapsed Patients with Multiple Myeloma - ASH abstract - November 2017 (Yimer)
URL
N/A
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX - ASH abstract - November 2017 (van de Donk)
URL
N/A
Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone vs Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial - ASH abstract - November 2017 (Maiese)
URL
N/A
Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results - ASH abstract - November 2017 (Plesner)
URL
N/A

Page: First Previous
1
2
3
4
5
6
...
19
Next Last

 
 
 

Please be advised that additional documents and media, such as fact sheets and conference call webcasts, are available only in English and can be accessed by clicking on the English tab.

 

Download Library
Document Type
Genmab offentliggør resultat for de første ni måneder af 2012 og opjusterer forventningerne til 2012
pdf
233.3 KB
Genmab offentliggør resultat for første halvår 2012 og opjusterer forventningerne til 2012
pdf
321.8 KB
Genmab offentliggør resultat for første kvartal 2012
pdf
231.7 KB
Overordnede retningslinjer for incitamentsordninger
PDF
79.0 KB
Lovpligtig redegørelse for virksomhedsledelse 2011
PDF
129.3 KB
Lovpligtig redegørelse for samfundsansvar 2011
PDF
31.7 KB
Årsrapport 2011
PDF
1.8 MB
Lovpligtig redegørelse for virksomhedsledelse 2010
PDF
131.1 KB
Genmab offentliggør resultat for de første ni måneder af 2011 og opdaterede resultatforventninger til 2011
PDF
287.4 KB
Delårsrapport pr. 30. juni 2011
PDF
286.0 KB
Delårsrapport for 1. kvartal 2011
PDF
278.3 KB
Årsregnskabsmeddelelse 2010
PDF
686.1 KB
Delårsrapport pr. 30. september 2010
PDF
248.7 KB
Delårsrapport pr. 30. juni 2010
PDF
328.8 KB
Delårsrapport for 1. kvartal 2010
PDF
293.7 KB
Årsrapport 2010
PDF
2.5 MB
Årsregnskabsmeddelelse 2009
PDF
688.2 KB
Årsrapport 2009
PDF
2.5 MB
Delårsrapport pr. 30. september 2009
PDF
319.1 KB
Delårsrapport pr. 30. juni 2009
PDF
161.1 KB
Delårsrapport for 1. kvartal 2009
PDF
192.8 KB
Årsregnskabsmeddelelse 2008
PDF
518.9 KB
Årsrapport 2008
PDF
3.7 MB
Kvartalsrapport for perioden 1. januar til 30. september 2008
PDF
181.5 KB
Halvårsrapport pr. 30. juni 2008
PDF
212.3 KB
Page: First Previous
1
2
3
4
Next Last